Keensight

website
https://keensight.com/
investment date
2024
leader
Jean-Michel Beghin

Keensight invests in B2B healthcare service companies (diagnostics, medtechs, software, CROs, CDMOs, prosthetics, etc.) whose offerings are essential to the smooth running of the medical industry.

No items found.

Why Auræ chose this project

Keensight is one of the most successful growth funds in France and Europe, with a particular focus on healthcare software and technology. As such, we are delighted to benefit from their expertise and to indirectly support companies with a strong impact on public health. In Keensight's portfolio, we focus particularly on:

3P

Development and manufacturing of biopharmaceuticals and cell therapy products

Axxam

Leading CRO in drug discovery

Dedienne Santé

Design, manufacturing and marketing of orthopedic implants

Lisam

Software and services for chemical supply compliance